Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.51 |
| ▸ | DRD2 | P14416 | 10/20 | 0.51 |
| ▸ | HTR7 | P34969 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 7/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85223 | 0.84 | DRD2 (0.55) | HTR2ADRD2HTR7KCNH2HTR1A | |
| SCHEMBL2734696 | 0.82 | DRD2 (0.49) | HTR2ADRD2HTR7 | |
| SCHEMBL84562 | 0.80 | DRD2 (0.53) | HTR2ADRD2HTR7HTR1A | |
| SCHEMBL13451119 | 0.77 | DRD2 (0.52) | HTR2ADRD2HTR7HTR1A | |
| SCHEMBL85011 | 0.76 | DRD2 (0.58) | HTR2ADRD2HTR7KCNH2HTR1A | |
| SCHEMBL85001 | 0.73 | DRD2 (0.57) | HTR2ADRD2HTR7HTR1A | |
| SCHEMBL21678227 | 0.73 | DRD2 (0.59) | HTR2ADRD2HTR7KCNH2HTR1A | |
| SCHEMBL21678228 | 0.72 | DRD2 (0.54) | HTR2ADRD2HTR7KCNH2HTR1A | |
| SCHEMBL84565 | 0.72 | HTR2A (0.61) | HTR2ADRD2HTR7KCNH2HTR1A | |
| SCHEMBL85231 | 0.72 | HTR2A (0.58) | HTR2ADRD2HTR7KCNH2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129410-B2 | Sleep maintenance insomnia; circadian rhythm abnormalities; side effect reduction | HYPNION, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129410-B2 | Sleep maintenance insomnia; circadian rhythm abnormalities; side effect reduction | HYPNION, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-1877405-B1 | BENZISOXAZOLE PIPERIDINE COMPOUNDS AND METHODS OF USE THEREOF | HYPNION INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | HYPNION, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | HYPNION, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | GABRA5, GABRE, HCRTR2 | HTR2A 284/4885DRD2 1344/4885HTR7 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.